BeOne Medicines has announced a 300 million dollar expansion of its flagship manufacturing and research campus in Hopewell, New Jersey, pushing the company’s total US manufacturing investment past 1 billion dollars. The Switzerland domiciled global oncology company, listed as Nasdaq: ONC, HKEX: 06160 and SSE: 688235, will add a new three story, 145,000 square foot building at its Princeton West Innovation Campus to house small molecule drug manufacturing, packaging operations, quality control labs and office space. The addition will sit alongside the campus’s existing biologics production, turning the site into a fully integrated, multi platform manufacturing facility. Once complete, the campus footprint will grow to approximately 545,000 square feet across the 42 acre site, which still has more than 1 million square feet of developable land for future growth. The Princeton West Innovation Campus opened in July 2024 following an initial 800 million dollar investment, meaning the new expansion effectively doubles down on a facility barely two years into operation. BeOne says the added capacity will support its oncology pipeline of more than 35 clinical and commercial stage assets, reinforcing New Jersey’s role as what the state’s governor calls the medicine chest of the world.

New Jersey’s Industrial and Life Sciences Corridor Keeps Growing

BeOne’s expansion lands amid a broader wave of industrial and life sciences construction across central New Jersey, a region long favored by developers for its port access, highway network and skilled workforce. Construction Review Online reported in 2022 that Advance Realty and Greek Development had secured a combined 227 million dollar loan for the Linden Logistics Center and Logan North Industrial Park projects, two large scale warehouse developments in Linden and Logan Township. Both projects have since moved well beyond that financing round. Linden Logistics Center is now fully built out at 4.1 million square feet and roughly 82 percent leased to tenants including Samsung, Peloton and World Distribution Services, and the developers, now operating as Greek Real Estate Partners, secured a fresh 300 million dollar refinancing on part of the complex in 2025. Logan North has continued adding tenants as well, including a recent build to suit deal for outdoor storage space. The pattern across these projects and BeOne’s Hopewell campus is the same: New Jersey’s industrial and pharmaceutical real estate markets keep attracting large, repeat rounds of capital well after a project’s initial delivery, a sign of sustained demand rather than a one time building boom.

BeOne Medicines Hopewell Timeline and What Comes Next

The New Jersey Economic Development Authority board approved a Next New Jersey Manufacturing Program award for BeOne on July 22, 2026, backing the expansion with a 33.9 million dollar tax credit distributed over five years, the second award granted under that program. BeOne qualified after exceeding the program’s minimum investment and job creation thresholds. The company expects the new small molecule building to be fully operational in 2029, with headcount at the Hopewell site rising to approximately 240 employees by that point, up from current levels. BeOne has credited both state incentives and federal tax policies favoring biopharmaceutical production for supporting the decision to keep expanding domestically rather than overseas. No groundbreaking date has been announced publicly, and the main construction contractor has not yet been disclosed, leaving the exact build schedule as the main open question heading into the next phase.

Project Fact Sheet

• Project Name: BeOne Medicines Princeton West Innovation Campus Expansion
• Location: Hopewell Township, Mercer County, New Jersey
• Project Value: 300 million dollars, bringing total campus investment to more than 1 billion dollars
• Client/Owner: BeOne Medicines Ltd., through BeOne Medicines US Manufacturing Co.
• Key Components: New three story, 145,000 square foot building for small molecule manufacturing, packaging, quality control labs and offices, added to existing biologics production
• Procurement Model: Privately financed, supported by a New Jersey Economic Development Authority tax credit
• Construction Start: Not yet publicly announced, following NJEDA approval on July 22, 2026
• Expected Completion: Fully operational in 2029
• Jobs Created: About 120 new full time jobs, with site headcount reaching approximately 240 by the end of 2029
• Environmental/Social Features: Expansion reuses existing campus land within the 42 acre site rather than requiring a new greenfield location
• Strategic Impact: Creates a fully integrated, multi platform manufacturing hub supporting more than 35 clinical and commercial stage oncology assets

Project Team

• Client/Owner: BeOne Medicines Ltd.
• Manufacturing Subsidiary: BeOne Medicines US Manufacturing Co.
• Incentive Provider: New Jersey Economic Development Authority
• Main Contractor: Not yet disclosed

Frequently Asked Questions

How much is BeOne Medicines investing in its Hopewell New Jersey expansion? BeOne is investing 300 million dollars in the new building, bringing its total investment at the campus to more than 1 billion dollars.

When will BeOne’s expanded Hopewell facility be operational? The company expects the new small molecule manufacturing building to be fully operational in 2029.

How many jobs will the BeOne Medicines expansion create? The project is expected to create about 120 new full time jobs, with site headcount reaching roughly 240 by the end of 2029.

What will BeOne’s expanded Hopewell campus manufacture? The new building adds small molecule drug manufacturing and packaging alongside the campus’s existing biologics production.

What incentives is BeOne Medicines receiving for its New Jersey expansion? The New Jersey Economic Development Authority approved a 33.9 million dollar tax credit under its Next New Jersey Manufacturing Program, distributed over five years.